Economic Impact of Using an Immunostimulating Agent to Prevent Severe Acute Exacerbations in Patients with Chronic Obstructive Pulmonary Disease | Zendy

JeanPaul Collet | Zendy; Thiérry Ducruet | Zendy; Seema Haider | Zendy; Stan Shapiro | Zendy; Ann Robinson | Zendy; Paolo Renzi | Zendy; AndréPierre Contandriopoulos | Zendy; Pierre Ernst | Zendy

Open Access

Economic Impact of Using an Immunostimulating Agent to Prevent Severe Acute Exacerbations in Patients with Chronic Obstructive Pulmonary Disease

Author(s) -

JeanPaul Collet,

Thiérry Ducruet,

Seema Haider,

Stan Shapiro,

Ann Robinson,

Paolo Renzi,

AndréPierre Contandriopoulos,

Pierre Ernst

Publication year - 2001

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2001/508015

Subject(s) - medicine , placebo , exacerbation , pulmonary disease , randomized controlled trial , intensive care medicine , acute exacerbation of chronic obstructive pulmonary disease , alternative medicine , pathology

OM-85 BV, an immunostimulant made from bacterial extracts, has been shown to reduce the risk of hospitalization for acute exacerbation in patients with chronic obstructive pulmonary disease, as well as to reduce the length of stay for all hospitalizations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research